Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2007-10-16
2007-10-16
Nickol, Gary B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C530S351000
Reexamination Certificate
active
10797157
ABSTRACT:
Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.
REFERENCES:
patent: 2003/0157105 (2003-08-01), Carton et al.
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 02/29060 (2002-04-01), None
patent: WO 02/097048 (2002-12-01), None
DeJong et al., A single cDNA, hTFIIA/alpha, encodes both the p35 and p19 subunits of human TFIIA. Genes Dev., 1993, 7(11):2220-34, (abstract only).
Broberg, et al. (2002)J. Interferon Cytokine Res.22:641-651 “Herpes Simplex Virus Type 1 Infection Induces Upregulation of Interleukin-23 (p19) mRNA Expression in Trigeminal Ganglia of BALB/c Mice”.
Cannistra and Niloff (1996)New Engl. J. Med.334:1030-1038 “Cancer of the Uterine Cervix”.
Cooper, et al. (2002)J. Immunol.168:1322-1327 “Mice Lacking Bioactive IL-12 Can Generate Protective, Antigen-Specific Cellular Responses to Mycobacterial Infection Only if the IL-12 p40 Subunit Is Present”.
Cua, et al. (2003)Nature421:744-748 “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain”.
Elkins, et al. (2002)Infection Immunity70:1936-1948 “In Vivo Clearance of an Intracellular Bacterium,Francisella tulatensisLVS, Is Dependent on the p40 Subunit of Interleukin-12 (IL-12) but Not on IL-12 p70”.
Enzinger and Mayer (2003)New Engl. J. Med.349:2241-2252 “Esophageal Cancer”.
Farrar, et al. (1999)J. Immunol.162:2842-2849 “Cancer Dormancy. VII. A Regulatory Role for CD8+T Cells and IFN-yin Establishing and Maintaining the Tumor-Dormant State”.
Fischer, et al. (1997)Nature Biotechnol.15:142-145 “A bioactive designer cytokine for human hematopoietic progenitor cell expansion”.
Forastiere, et al. (2001)New Engl. J. Med.345:1890-1900 “Head and Neck Cancer”.
Frucht (2002)Sci STKE2002, E1-E3 “IL-23: A Cytokine That Acts on Memory T Cells”.
Izbicki, et al. (1997)New Engl. J. Med.337:1188-1194 “Prognostic Value of Immunohistochemically Identifiable Tumor Cells in Lymph Nodes of Patients with Completely Resected Esophageal Cancer”.
Le, et al. (2001)J. Immunol.167:6765-6772 “Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12”.
Lynch and Chapelle (2003)New Engl. J. Med.348:919-932 “Hereditary Colorectal Cancer”.
Oppmann, et al. (2000)Immunity13:715-725 “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”.
Osborne (1998)New Engl. J. Med.339:1609-1618 “Tamoxifen In the Treatment of Breast Cancer”.
Parham, et al. (2002)J. Immunol.168:5699-5708 “A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R”.
Peters, et al.(1998)J. Immunol.161:3575-3581 “In Vivo and In Vitro Activities of the gp130-Stimulating Designer Cytokine Hyper-IL-6”.
Pirhonen, et al. (2002)J. Immunol.169:5673-5678 “Regulation of Virus-Induced IL-12 and IL-23 Expression in Human Macrophages”.
Rakemann, et al. (1999)J. Biol. Chem.274:1257-1266 “The Designer Cytokine Hyper-Interleukin-6 Is a Potent Activator of STAT3-dependent Gene Transcription in Vivo and in Vitro”.
Ramirez-Montagut, et al. (2003)Oncogene22:3180-3187 “Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity”.
Sawaya, et al. (2003)New Engl. J. Med.349:1501-1509 “Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings”.
Wiekowski, et al. (2001)J. Immunol.166:7563-7570 “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death”.
Ugai, et al. (2003)Cancer Gene Therapy10:771-778 “Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects”.
Lo, et al. (2003)J. Immunol.171:600-607 “Antitumor and Antimetastatic Activity of IL-23”.
Coussens and Werb, Insight review articles: Inflammation and cancer, Nature (2002), vol. 420, pp. 860-867.
McClanahan Terrill K.
Oft Martin
Bellomy Gregory R.
Jiang Dong
Mohan-Peterson Sheela
Nickol Gary B.
Schering Corporation
LandOfFree
Uses of IL-23 agonists and antagonists; related reagents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of IL-23 agonists and antagonists; related reagents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of IL-23 agonists and antagonists; related reagents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834506